Live Quote · NASDAQPPBTHealthcare· Biotechnology

Purple Biotech Ltd.

$1.70 2.86%($-0.05)
TickerSpark Score
44/100
Weak
90
Valuation
20
Profitability
15
Growth
64
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPBT research report →

52-Week Range1% of range
Low
$1.42
Current
$1.70
High
$29.00
Company Overviewpurple-biotech.com

About the company

Purple Biotech Ltd. , a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).

CEO
Gil Efron
IPO
2015
Employees
9
HQ
Rehovot, IL

Price Chart

-92.92% · this period
$27.75$14.64$1.54Jul 02Dec 31Jul 02
Valuation
Market Cap
$234.74K
P/E
-0.01
P/S
0.00
P/B
0.63
EV/EBITDA
0.49
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-123.47%
ROIC
-297.05%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-26,386,000 · -264.45%
EPS
$-11080.00 · -24967.87%
Op Income
$-27,458,000
FCF YoY
61.44%
Performance & Tape
52W High
$29.00
52W Low
$1.42
50D MA
$3.05
200D MA
$5.35
Beta
-0.54
Avg Volume
307.33K

Get TickerSpark's AI analysis on PPBT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 18, 26Rock Simchaother0
Mar 18, 26Rock Simchaother2,650,000
Mar 18, 26Zilberberg Suzanaother0
Mar 18, 26Zilberberg Suzanaother2,650,000
Mar 18, 26Agmon Idoother0
Mar 18, 26Agmon Idoother2,650,000
Mar 18, 26Efron Gilother0
Mar 18, 26Efron Gilother13,500,000
Mar 18, 26Schickler Michaelother0
Mar 18, 26Schickler Michaelother7,100,000
Coverage · PPBT

Our PPBT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on PPBT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate PPBT report →
Internal Compare

Similar companies

Peers in the same neighborhood.